U.S. SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

(Mark One)
  X      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
-----    ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000

__       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934 FOR THE TRANITION PERIOD FROM ___________ TO ______________

Commission File Number 2-93277-D

                          MEDIZONE INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

Nevada                                                 87-0412648
(State or other jurisdiction                (I.R.S. Employer Identification No.)
of incorporation or organization)

                                 144 Buena Vista
                                  P.O. Box 742
                             Stinson Beach, CA 94970
               (Address of principal executive offices, Zip Code)

                                 (415) 868-0300
              (Registrant's telephone number, including area code)

 Check whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

At November 9, 2000,  there were 153,915,798  shares of the registrant's  common
stock issued and outstanding.

Transitional Small Business Disclosure Format
(Check one):
Yes __ No X
          ----


                                       1


<PAGE>


                          MEDIZONE INTERNATIONAL, INC.
                                   FORM 10-QSB
                                      INDEX
                               September 30, 2000

                                                                          Page
                                                                         Number

Part I - Financial Information

Item 1 - Financial Statements

            Consolidated Balance Sheet:
         -September 30, 2000 and December 31, 1999..........................3

            Consolidated Statement of Operations:
         -For the Three Months and Nine Months Ended September .............4
          30, 2000 and 1999

        Consolidated Statement of Cash Flow
         -For the Nine Months Ended

           September 30, 2000 and 1999......................................5

             Notes to Consolidated Financial Statements.....................6

Item 2 - Management's Discussion and Analysis or Plan of Operation..........7

Part II - Other Information

Item 6 - Exhibits and Reports on Form 8-K .................................10



                                       2


<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                    September 30, 2000 and December 31, 1999


<TABLE>
<CAPTION>
                                                           ASSETS

                                                                     September 30,           December 31,
                                                                          2000                   1999
                                                                  ---------------------    ------------------
CURRENT ASSETS                                                        (Unaudited)
<S>                                                               <C>                      <C>
    Cash and cash equivalents                                     $              8,918     $           4,388
                                                                  ---------------------    ------------------
        Total Current Assets                                                     8,918                 4,388
                                                                  ---------------------    ------------------

PROPERTY AND EQUIPMENT, net                                                     16,572                 5,667
                                                                  ---------------------    ------------------

                                                                  $             25,490     $          10,055
                                                                  =====================    ==================

                                  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES
    Accounts payable                                              $            245,184     $         395,370
    Accrued expenses                                                           406,374               527,045
    Current portion of long-term obligations                                   280,491               280,491
                                                                  ---------------------    ------------------
        Total Current Liabilities                                              932,049             1,202,906
                                                                  ---------------------    ------------------

STOCKHOLDERS' EQUITY (DEFICIT)
    Common stock                                                               153,616               149,888
    Additional paid-in capital                                              13,165,754            12,676,882
    Deficit accumulated during the development stage                       (14,225,929)          (14,019,621)
                                                                  ---------------------    ------------------
        Total Stockholders' Equity (Deficit)                                  (906,559)           (1,192,851)
                                                                  ---------------------    ------------------

                                                                  $             25,490     $          10,055
                                                                  =====================    ==================
</TABLE>



                             See accompanying notes.

                                       3

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS



<TABLE>
<CAPTION>
                                                Three          Three          Nine           Nine
                                               Months         Months         Months         Months
                                                Ended          Ended         Ended          Ended
                                               9/30/00        9/30/99       9/30/00        9/30/99
                                            -------------- -------------- -------------  -------------

<S>                                         <C>            <C>            <C>            <C>
REVENUE                                     $           -  $           -  $          -   $          -
COST OF SALES                                           -              -             -              -
                                            -------------- -------------- -------------  -------------
  Gross Profit                                          -              -             -              -
                                            -------------- -------------- -------------  -------------

COSTS AND EXPENSES
  Research and development                          7,585              -        88,392              -
  Depreciation and amortization                     1,595            486         4,026          1,459
  General and administrative                      144,181         14,626       512,061         54,991
                                            -------------- -------------- -------------  -------------
     Total Costs and Expenses                     153,361         15,112       604,479         56,450
                                            -------------- -------------- -------------  -------------

LOSS BEFORE OTHER INCOME (EXPENSE)               (153,361)       (15,112)     (604,479)       (56,450)
                                            -------------- -------------- -------------  -------------

OTHER INCOME (EXPENSE)
  Restitution proceeds                                  -              -       415,000              -
  Interest expense                                 (5,610)        (5,609)      (16,829)       (16,829)
  Interest income                                       -              -             -              -
                                            -------------- -------------- -------------  -------------
     Total Other Income (Expense) - net            (5,610)        (5,609)      398,171        (16,829)
                                            -------------- -------------- -------------  -------------

LOSS BEFORE INCOME TAXES                         (158,971)       (20,721)     (206,308)       (73,279)

INCOME TAX BENEFIT (PROVISION)                          -              -             -              -
                                            -------------- -------------- -------------  -------------

NET LOSS                                       $ (158,971)     $ (20,721)   $ (206,308)     $ (73,279)
                                            ============== ============== =============  =============

NET LOSS PER COMMON
  SHARE
  Basic                                           $ (0.00)       $ (0.00)      $ (0.00)       $ (0.00)
                                            ============== ============== =============  =============

AVERAGE COMMON AND EQUIVALENT
  SHARES
  Basic                                       153,615,798    149,148,656   154,191,354    149,123,965
                                            ============== ============== =============  =============
</TABLE>


                             See accompanying notes.

                                       4

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
              For the Nine Months Ended September 30, 2000 and 1999



<TABLE>
<CAPTION>
                                                                September 30,        September 30,
                                                                     2000                1999
                                                               -----------------   ------------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                            <C>                         <C>
     Net loss                                                  $       (206,308)   $         (73,279)
     Adjustments to reconcile net loss to net
             cash provided by operating activities
         Depreciation and amortization                                    4,026                1,459
         Issuance of stock for services                                 272,600                    -
     Change in operating assets and liablilites
         Accounts payable and other liabilities                        (270,857)              48,643
                                                               -----------------   ------------------
                                                                       (200,539)             (23,177)
                                                               -----------------   ------------------

CASH FROM INVESTING ACTIVITIES
     Acquisition of property and equipment                              (14,931)                   -
                                                               -----------------   ------------------
                                                                        (14,931)                   -
                                                               -----------------   ------------------

CASH FROM FINANCING ACTIVITIES
     Proceeds from issuance of common stock                             220,000               15,556
                                                               -----------------   ------------------
                                                                        220,000               15,556
                                                               -----------------   ------------------

NET CHANGE IN CASH AND CASH EQUIVALENTS                                   4,530               (7,621)

CASH AND CASH EQUIVALENTS
     Beginning of period                                                  4,388                7,643
                                                               -----------------   ------------------
     End of period                                             $          8,918    $              22
                                                               =================   ==================

SUPPLEMENTAL CASH FLOW INFORMATION
     Cash paid during the period for:
         Interest                                              $              -    $               -
                                                               =================   ==================
         Income taxes                                          $              -    $               -
                                                               =================   ==================

NON-CASH INVESTING AND FINANCING
     ACTIVITIES
     Issuance of common stock for services                     $              -    $               -
                                                               =================   ==================
</TABLE>



                             See accompanying notes.

                                       5

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1 - Basis of Presentation

The  financial  information  included  herein is unaudited and has been prepared
consistent with generally accepted  accounting  principles for interim financial
information  and  with the  instructions  to Form  10-QSB  and  Item  310(b)  of
Regulation  S-B.  Accordingly,  these  financial  statements  do not include all
information and footnotes required by generally accepted  accounting  principles
for  complete  financial   statements.   These  statements  should  be  read  in
conjunction with the audited financial  statements and notes thereto included in
the Company's annual report on Form 10-KSB for the year ended December 31, 1999.
In the opinion of management, these financial statements contain all adjustments
(consisting solely of normal recurring adjustments) which are, in the opinion of
management,  necessary  for a fair  statement of results for the interim  period
presented.

The results of operations for the nine months ended  September 30, 2000 and 1999
are not necessarily indicative of the results to be expected for the full year.

2 - Loss Per Share

Following is a  reconciliation  of the  numerators of the basic and diluted loss
per share for the three and nine months ended September 30, 2000 and 1999:

3 - Capital Stock

<TABLE>
<CAPTION>
                                                Three          Three          Nine           Nine
                                               Months         Months         Months         Months
                                                Ended          Ended         Ended          Ended
                                               9/30/00        9/30/99       9/30/00        9/30/99
                                            -------------- -------------- -------------  -------------
Net  loss available to common
<S>                                         <C>            <C>            <C>            <C>
  shareholders                              $    (158,971) $     (20,721) $   (206,308)  $    (73,279)
                                            ============== ============== =============  =============

Weighted average shares                       153,615,798    149,148,656   154,191,354    149,123,965
Effect of dilutive securities                           -              -             -              -
                                            -------------- -------------- -------------  -------------

                                              153,615,798    149,148,656   154,191,354    149,123,965
                                            ============== ============== =============  =============

Basic loss per share (based on
  weighted average shares)                  $       (0.00) $       (0.00) $      (0.00)  $      (0.00)
                                            ============== ============== =============  =============
</TABLE>



During the quarter  ended  September  30,  2000,  2,000,000  common  shares were
canceled by the Company.

                                       6

<PAGE>


Item 2 - Management's Discussion and Analysis or Plan of Operation

The following  discussion and analysis of the Company's  financial condition and
results of operations should be read in conjunction with the unaudited Condensed
Consolidated  Financial Statements and Notes thereto appearing elsewhere in this
Quarterly Report on Form 10-QSB.

The Company is a development  stage company,  primarily  engaged in research and
development of ozone-based  treatment for diseases and health problems caused by
lipid enveloped  viruses,  including,  for example,  Acquired Immune  Deficiency
Syndrome (AIDS),  Hepatitis B, Hepatitis C and Herpes, and in the development of
technology for the  decontamination  of blood,  blood products and  veterinarian
serum  products.  The  Company is also  pursuing  the  development  of  external
applications of its technology for medical purposes.

The Company has not  generated,  and cannot predict when or if it will generate,
significant revenues or sufficient cash flow to fund its continuing  operations.
It has  funded  its  operations  to  date  primarily  through  the  sale  of its
securities.  The  technology and its uses are subject to regulations of the U.S.
Food and Drug Administration  ("FDA") and its counterparts in foreign countries.
The Company does not intend to sell  equipment or supplies for  ozone-generating
purposes until it receives required government approvals.

Testing and trials can be conducted on a limited basis for research purposes and
to  establish  efficacy  of  machines  and  applications,  in order  to  support
applications  for government  approvals.  In November of 1997,  Dr. Sunnen,  the
Director of Research (who later was appointed  president of the Company on April
15, 1998) was  instrumental in establishing a protocol for Phase II research.  A
double  blind  Phase II human  trial into HCV is now in the  planning  stage and
should be announced in the next 90 days.

The Company has also  conducted  a  proof-of-concept  pilot trial study on forty
patients  infected with Hepatitis C. This study was conducted under the guidance
of Dr.  William Hitt, a former member of the Company's  Board of Directors.  The
trial,  conducted during the normal course of Dr. Hitt's medical practice at his
clinic in Mexico,  indicated  significant  reductions  in liver enzyme levels as
measured by SGOT and SGPT standard test procedures of the patients participating
in the study. All of the patients' SGOT and SGPT measures returned to the normal
range.  In  addition  on  average,  5 log viral load  reductions  (99.9%)  were
achieved.  Six-month post treatment  viral load tests,  without  further medical
intervention  during  that  time,  indicated  the  viral  load  during  the post
treatment  period  did  not  increase  in 38 of the 40  patients.  In two of the
patients, both of which were genotype 1A, there was a viral load increase in the
six-month post treatment period. No toxic side effects were reported or observed
in any of the patients.

In March 2000,  the Company  received  notification  that it had been  granted a
patent by the US Patent and  Trademark  Office on its  application  for a patent
covering the external  applications  of ozone for medical  purposes.  The patent
application,  no.  09/126,504,  had been filed on July 30, 1998.  Problems  that
might be  addressed  by such uses  would  include  treatment  of  severe  burns,
infections  of  ulcerations  of the skin  (such as those that might be caused by
advanced  stages of diabetes) or other wounds.  In  connection  with this use of
ozone, the Company has been granted US Patent No. 9/126504,  titled External Use
of  Ozone/Oxygen  for  Pathogenic  Conditions.  Foreign  applications  are being
processed.

In May 2000, the Company filed another patent  application  no.  1299-4015 under
the title "Method and Apparatus for Ozone Decontamination of Biological Liquids.

In  addition,  the  Company  owns  patents  covering  its ozone  decontamination
technology filed in the United States (no. 4,632,980,  December 30, 1986 and no.
5,052,382,  October 1, 1991),  and related  patents  granted in several  foreign
countries. These patents form the basis for the Company's technology used in the
studies described above.

The Company has also been active in pursuing veterinary trials investigating the
effectiveness of ozone in deactivation of viruses in serum products. The Phase I
trial on healthy  serum  products  was  concluded in October 1999 and was deemed
successful by the  Company's  researchers.  Dr.  Sunnen  expects that a Phase II
trial should also be successful  based on the results of the first round. Due to
streamlining  of  equipment  development,  completion  of  Phase  II is not  now
anticipated prior to September of 2001.

There is no  assurance  that the  results  of such  tests  and  studies  will be
favorable to the Company or that  regulatory  approval will be received based on
such results.

                                       7

<PAGE>

Results of Operations

General

From its inception  (January  1986),  the Company has been a  development  stage
company  primarily  engaged in  research  into the  medical  uses of ozone.  The
Company  has not  generated,  and cannot  predict  when or if it will  generate,
revenues or sufficient cash flow to fund its continuing operations.

Three  Months  Ended  September  30,  2000  compared to the Three  Months  Ended
September 30, 1999:

There were no sales during the quarters  ended  September 30, 2000 or 1999.  The
Company made  expenditures  for research and  development of $7,585 in the third
quarter  of  2000  and  none  in  the  third   quarter  of  1999.   General  and
administrative  expenses in the third quarter of 2000 were $144,182  compared to
$14,626 during the third quarter of 1999.  These expenses  include  professional
fees, payroll, insurance costs and travel expenses.

Interest  expense  accrued during the three months ended  September 30, 2000 was
$5,610, compared to $5,609 in the three months ended September 30, 1999.

Nine Months Ended September 30, 2000 compared to the Nine Months Ended September
30, 1999:

There were no sales  during the nine months  ended  September  30, 2000 or 1999.
Cash of $415,000  was  provided  in the first  quarter of 2000 by the receipt of
restitution  payments  from a former  officer and  director.  The  Company  made
expenditures  for research and  development  of $88,392 in the nine months ended
September 30, 2000 and none in the nine months ended September 30, 1999. General
and  administrative  expenses in the nine months ended  September  30, 2000 were
$512,062  compared to $54,991  during the nine months ended  September 30, 1999.
These expenses include  professional fees,  payroll,  insurance costs and travel
expenses.

Interest  expense  accrued  during the nine months ended  September 30, 2000 was
$16,829, compared to $16,829 in the nine months ended September 30, 1999.

Liquidity and Capital Resources

At September 30, 2000, the Company had a working capital  deficiency of $923,131
and stockholders'  deficiency of $906,559. At December 31, 1999, the Company had
a working  capital  deficiency of  $1,198,518  and  stockholders'  deficiency of
$1,192,851.

Net cash used in  operating  activities  was  $200,539 for the nine months ended
September 30, 2000. During the nine months ended September 30, 1999, the Company
used $23,177 in operating activities. Cash of $415,000 was provided in the first
nine months of 2000 by the receipt of restitution payments from a former officer
and director and $220,000 was provided by the sale of the  Company's  securities
through the exercise of outstanding stock purchase warrants.

The Company  will  continue to require  additional  funding to enable it to fund
research necessary to make the appropriate  regulatory  application and continue
operations.  It is expected that these funds will be provided by the sale of the
Company's securities.

The Company has  developed a strategy,  which it believes will enable it to fund
requisite  research   necessary  to  gain  regulatory   approvals  and  continue
operations. This strategy depends upon the sale of the Company's common stock or
other  securities  to  certain  accredited  investors.   The  Company  has  also
structured and recently  implemented a cohesive  scientific plan  encompassing a
number of research initiatives,  which it believes may enable it to successfully
achieve its primary  goals.  Those goals include the  submission of  appropriate
research  data to the FDA Center for Drugs and Biologics for the approval of its
blood decontamination process and to the FDA Division of Antiviral Drug Products
for approval of Phase I human  clinical  trial status for the  treatment of AIDS
and Hepatitis. There can be no assurance that either the funding strategy or the
scientific plan will be successful.  Failure to obtain  requisite  funding would
have a materially adverse effect on the Company and its financial condition.

                                       8

<PAGE>

The Company recognizes that, if it is unable to raise additional capital, it may
find it necessary to substantially reduce, or cease operations.

Forward-Looking Statements and Risks Affecting the Company

The  statements  contained  in this  Report on Form  10-QSB  that are not purely
historical are  "forward-looking  statements"  within the meaning of the Private
Securities  Litigation  Reform  Act of 1995 and  Section  21E of the  Securities
Exchange  Act.  These  statements  regard  the  Company's  expectations,  hopes,
beliefs,  anticipations,  commitments,  intentions and strategies  regarding the
future.  They  may be  identified  by the  use  of  words  or  phrases  such  as
"believes,"  "expects,"   "anticipates,"  "should,"  "plans,"  "estimates,"  and
"potential,"  among  others.  Forward-looking  statements  include,  but are not
limited to,  statements  contained in  Management's  Discussion  and Analysis of
Financial Condition and Results of Operations  regarding the Company's financial
performance, revenue and expense levels in the future and the sufficiency of its
existing assets to fund future  operations and capital  spending  needs.  Actual
results  could  differ   materially  from  the  anticipated   results  or  other
expectations  expressed  in such  forward-looking  statements  for  the  reasons
detailed in the Company's Annual Report on Form 10-K for the year ended December
31, 1999 under the headings  "Description  of Business" and "Risk  Factors." The
fact that some of the risk  factors may be the same or similar to the  Company's
past reports filed with the Securities and Exchange  Commission  means only that
the risks are present in multiple periods. The Company believes that many of the
risks  detailed here and in the Company's SEC filings are part of doing business
in the  industry in which the Company  operates  and competes and will likely be
present in all periods reported.  The fact that certain risks are endemic to the
industry  does not lessen their  significance.  The  forward-looking  statements
contained  in this report are made as of the date of this Report and the Company
assumes no obligation to update them or to update the reasons why actual results
could differ from those  projected  in such  forward-looking  statements.  Among
others,  risks  and  uncertainties  that  may  affect  the  business,  financial
condition,  performance,  development,  and results of operations of the Company
include:

     o    rigorous  government  scrutiny  and  regulation  of the  products  and
          planned products of the Company;

     o    potential  effects of adverse  publicity  regarding  ozone and related
          technologies or industries;

     o    failure  of the  Company to sustain  or manage  growth  including  the
          failure to continue to develop new products; and

     o    the ability of the Company to obtain needed financing.

Part II - Other Information

Item 6 - Exhibits and Reports on Form 8-K

         (a)      Exhibits

                  Exhibit No.               Description

                  27                        Financial Data Schedule

                                       9

<PAGE>


                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

                                 MEDIZONE INTERNATIONAL, INC.
                                 (Registrant)

                                 /s/ Edwin G. Marshall
                                 ------------------------------
                                 Edwin G. Marshall, Chairman and Chief Executive
                                 Officer (Principal Executive Officer)

                                 /s/ Kevin R. Andersen
                                 ------------------------------
                                 Kevin R. Andersen, Chief Financial Officer
                                 (Principal Accounting Officer)



November 14, 2000